CAU, PIERRE,BOURGEOIS, PATRICE,BONNIOL, VINCENT,LEVY, NICOLAS
申请号：
CA2711569
公开号：
CA2711569C
申请日:
2008.12.31
申请国别(地区):
CA
年份:
2017
代理人:
摘要：
Treatment of side effects caused by anti-HIV treatments.Composition includes at least one hydroxymethylglutaryl-coenzyme A(HMG-CoA) reductase inhibitor, at least one farnesyl-pyrophosphatesynthase inhibitor, and at least one anti-HIV agent, in which theHMB-CoA reductase inhibitor is a molecule of the family of statinsor one of its physiologically acceptable salts, in which thefarnesyl-pyrophosphate synthase inhibitor is chosen from the groupcomprising a molecule of the aminobiphosphonate (NBP) family orone of its physiologically acceptable salts, and in which theanti-HIV agent is a protease inhibitor or a reverse transcriptaseinhibitor. One of the processes for treating an HIV-infectedpatient includes, in any order, the following steps: (i)administration of a mixture including at least onehydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor andat least one farnesyl-pyrophosphate synthase inhibitor and (ii)administration of an anti-HIV agent, in which the administrationsare concomitant, successive or alternative.
